Melphalan flufenamide - Oncopeptides

Drug Profile

Melphalan flufenamide - Oncopeptides

Alternative Names: J-1; Mel-flufen

Latest Information Update: 18 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oncopeptides
  • Class Amides; Amino acids; Antineoplastics; Fluorobenzenes
  • Mechanism of Action Alkylating agents; Caspase 3 stimulants; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Multiple myeloma
  • Discontinued Bladder cancer; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 14 Jun 2018 Updated safety and efficacy data from the phase II HORIZON trial in Multiple myeloma presented at the 23rd Congress of the European Haematology Association (EHA-2018)
  • 16 Apr 2018 Oncopeptides AB initiates enrolment in a phase I/II trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA and Spain (IV) (NCT03481556)
  • 14 Dec 2017 Adverse events and efficacy data from a phase I/II trial in Multiple myeloma presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top